BioSpace News Archive

Medifocus, Inc. announced its decision to terminate and suspend the registration of its stock with the Securities and Exchange Commission.

Aruvant Sciences (“Aruvant”),(SCD) will be presented today in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th annual meeting.

CSL Limited yesterday announced an update regarding the Vifor Pharma AG acquisition.

Curative Biotechnology Inc., a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced that Cary Sucoff has joined its Board of Directors as an independent director.

Aptose Biosciences Inc. announced that the company management team, along with guest key opinion leaders, will provide an update for the investment community on Thursday, June 2nd at 4:30 PM.

Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, announced that the Company will attend the American Thoracic Society 2022 Annual Meeting being held May 13 - 18, 2022 in San Francisco, CA.

Genmab A/S announced that multiple abstracts evaluating epcoritamab, an investigational subcutaneous bispecific antibody, will be presented at the European Hematology Association Annual Congress, being held in Vienna, Austria, and virtually, June 9-12.

Curis, Inc. announced that multiple abstracts have been accepted for presentation at the upcoming European Hematology Association 2022 Hybrid Congress, which will be held virtually and in-person in Vienna on June 9-12, 2022.

ReHeva Biosciences, a biopharmaceutical startup helping people live longer and healthier with cancer through botanically-derived complex drugs, is announcing the first patient enrolled and dosed in the Phase I Safety Trial for the company’s drug, RH324.

The OTCQB index is intended for development/venture stage companies and requires the Company to submit audited financials which adhere to GAAP standards and the company must be current with its SEC filings/reports -- Form 10-K Annual (audited), Form 10-Q Quarterly (unaudited), and the occasional Form 8-K .